Emmaus Life Sciences, Inc.
EMMA
$0.01
$0.00-1.02%
OTC PK
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 11.89M | 13.99M | 16.55M | 16.65M | 20.43M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 11.89M | 13.99M | 16.55M | 16.65M | 20.43M |
| Cost of Revenue | 931.00K | 1.08M | 1.17M | 1.20M | 1.08M |
| Gross Profit | 10.96M | 12.92M | 15.38M | 15.45M | 19.35M |
| SG&A Expenses | 11.27M | 13.49M | 14.87M | 16.69M | 18.64M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 12.62M | 15.08M | 16.69M | 18.55M | 20.41M |
| Operating Income | -729.00K | -1.09M | -134.00K | -1.89M | 18.00K |
| Income Before Tax | -7.29M | -3.97M | -4.40M | -6.42M | -3.59M |
| Income Tax Expenses | -1.00K | -581.00K | 40.00K | 29.00K | -89.00K |
| Earnings from Continuing Operations | -7.29 | -3.39 | -4.44 | -6.45 | -3.50 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -7.29M | -3.39M | -4.44M | -6.45M | -3.50M |
| EBIT | -729.00K | -1.09M | -134.00K | -1.89M | 18.00K |
| EBITDA | -700.00K | -1.07M | -113.00K | -1.87M | 41.00K |
| EPS Basic | -0.11 | -0.05 | -0.07 | -0.10 | -0.05 |
| Normalized Basic EPS | -0.06 | -0.04 | -0.04 | -0.07 | -0.04 |
| EPS Diluted | -0.12 | -0.06 | -0.07 | -0.11 | -0.06 |
| Normalized Diluted EPS | -0.06 | -0.04 | -0.04 | -0.07 | -0.04 |
| Average Basic Shares Outstanding | 255.46M | 255.46M | 254.95M | 252.93M | 244.24M |
| Average Diluted Shares Outstanding | 255.46M | 255.46M | 254.95M | 252.93M | 244.24M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |